Janice Tildon-Burton, MD
Obstetrics & Gynecology · Newark, DENPI 1265509228
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $587 of the $777 with a category attached, or 75.5%. It is spread thinly across 15 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $375, 5.3 times the $71 reported in 2019.
Across 34 payments — averaging $22.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$119
- Millicent US Inc$110
- Mylan Pharmaceuticals Inc.$96
- Exeltis, USA Inc.$90
- Evofem Biosciences, Inc.$70
- Viiv Healthcare Company$63
- plus $230 from 9 others
What the payments were for
- Food & beverage$58776%
- Education$19024%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 2 | $119 |
| Millicent US Inc | 2 | $110 |
| Mylan Pharmaceuticals Inc. | 6 | $96 |
| Exeltis, USA Inc. | 3 | $90 |
| Evofem Biosciences, Inc. | 5 | $70 |
| Viiv Healthcare Company | 1 | $63 |
| AbbVie | 3 | $44 |
| Therapeuticsmd, Inc. | 2 | $34 |
| Sumitomo Pharma America, Inc. | 2 | $32 |
| Amgen | 2 | $29 |
| Myovant Sciences Inc. | 2 | $28 |
| Organon | 1 | $23 |
| Mission Pharmacal Company | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Bayer | 1 | $11 |
How this compares
$777 in reported general payments places this provider in the 65th percentile of 139 obstetrics & gynecology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 46 | $3,713 |
| Ibandronate Sodium | 16 | $852 |
| ValacyclovirValacyclovir Hcl | 21 | $592 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Newark
- Anthony BellNewark$17K
- Richard DermanNewark$14K
- Gordon OstrumNewark$4K
- Colleen DeturkNewark$4K
- Patricia CiranniNewark$3K
- Michelle PacisNewark$3K
- Gregory DemeoNewark$3K
- Jose PicazoNewark$2K
- David FinkNewark$2K
- Stefanie MarshallNewark$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.